AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.
AbbVie (NYSE:ABBV) completed its acquisition of Apogee Therapeutics (NASDAQ:APGE), paying $135.11 per share in cash for an equity value of approximately $10.9 billion as of September 3, 2026.
AbbVie (NYSE:ABBV) submitted a regulatory application to the European Medicines Agency for subcutaneous SKYRIZI (risankizumab) induction treatment in adults with moderately to severely active Crohn’s disease.
AbbVie (NYSE:ABBV) said the CHMP has issued a positive opinion recommending approval of upadacitinib (RINVOQ) 15 mg and 30 mg once daily for adults and adolescents with severe alopecia areata in the EU.
AbbVie (NYSE:ABBV) announced a multi-year collaboration with Iambic Therapeutics to apply artificial intelligence technologies to discover and develop small molecule therapies.
